Literature DB >> 15599118

Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade.

Michael Weber, Jan Basile, Joseph Izzo, Suzanne Oparil.   

Abstract

This roundtable discussion, held in December 2003, was convened to discuss the impact of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure's (JNC 7) challenging blood pressure goal objectives for the clinical management of hypertensive patients. The discussion was moderated by Michael Weber, MD, of the State University of New York Downstate College of Medicine in New York City. Participants included leading experts in the field Joseph Izzo, Jr., MD, of the School of Medicine and Biomedical Sciences at the State University of New York at Buffalo; Suzanne Oparil, MD, of the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham; and Jan Basile, MD, of the Ralph H. Johnson VA Medical Center and Department of General Internal Medicine/Geriatrics, Medical University of South Carolina in Charleston. The primary intention of this roundtable is to educate physicians about the importance of achieving the blood pressure goals agreed upon by the JNC 7 Committee and to present practical ways for the attainment of such goals in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599118      PMCID: PMC8109338          DOI: 10.1111/j.1524-6175.2004.03737.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  25 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group.

Authors:  J M Flack; C Yunis; J Preisser; C B Holmes; G Mensah; B McLean; E Saunders
Journal:  Arch Intern Med       Date:  2000-06-26

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.

Authors:  Ramachandran S Vasan; Alexa Beiser; Sudha Seshadri; Martin G Larson; William B Kannel; Ralph B D'Agostino; Daniel Levy
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

6.  Angiotensin receptor blockers: evidence for preserving target organs.

Authors:  P Carson; T Giles; M Higginbotham; N Hollenberg; W Kannel; H M Siragy
Journal:  Clin Cardiol       Date:  2001-03       Impact factor: 2.882

7.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 8.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.

Authors:  M Law; N Wald; J Morris
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

10.  Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.

Authors:  Joel M Neutel; David H G Smith; Michael A Weber; Antonia C Wang; Harvey N Masonson
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

View more
  1 in total

1.  Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.

Authors:  Thomas D Giles; Suzanne Oparil; Tonous N Silfani; Antonia Wang; J Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-03       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.